The high tumor uptake of both TTCs may also explain why statistically significant tumor growth inhibition was achieved for both PD-L1 TTC and isotype Th-227 conjugate as a monotherapy and in combination with PD-1 check-point inhibition (Figure 4). The gene discussed is CD274; the disease is neoplasm.